International Mammalian Genome Society

logo18th International Mouse Genome Conference

17-22 October 2004, Seattle, USA


Motegi H 1, Ohtaki M 2, Toki H 1, Inoue M 1, Masuya H 1, Kaneda H 1, Kobayashi K 1, Suzuki T 1, Wada Y 1, Wakana S 1, Minowa O 1, Gondo Y 3, Shiroishi T 1, Noda T 1

1 Mouse Functional Genomics Research Group, RIKEN GSC, Tsukuba, Japan, 2 Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, 3 Population and Quantitative Genomics Team, RIKEN, GSC, Yokohama, Japan

To identify mouse models of human diseases, we are running a blood test screening in a large-scale ENU mutagenesis program in RIKEN GSC since 2000. The blood test screening system consists of hematological test and clinical biochemical test. For each test, blood samples are collected at early onset stage (9 weeks for hematology and 11 weeks for clinical biochemistry) and late onset stage (52 weeks for hematology and 54 weeks for clinical biochemistry).

For dominant screening, we have screened so far about 10000 mice for early onset stage and about 2000 for late onset stage in each test. In early hematological test, about 70 of phenodeviants were tested for heritability and half of phenodeviants were inherited. In the case of early clinical biochemical test, about 200 phenodeviants were preceded to the inheritance test and one forth of them showed heritability. In late onset screening, about 100 phenodeviants including hematological and clinical biochemical test were identified. Inheritance tests for late onset screening are in progress.

Furthermore, recessive screening has started and about 300 mice of 20 pedigrees were screened for early onset screening of each test.

In this presentation, progress of blood screening in RIKEN mouse mutagenesis project will be reported and the feature of early onset, late onset and dominant, recessive screenings from the analysis of large amount of accumulated data will be discussed.

[an error occurred while processing this directive]